Edit

Qiming Venture Partners

https://www.qimingventures.com
Last activity: 29.04.2026
Active
Invests in categories: AIBioTechDevelopmentHealthTechMedTechPlatformProductProviderServiceTechnology
Qiming Venture Partners is a top-tier VC firm with outstanding reputation. With our exceptional investment performances, we have been widely recognized by investors from around the world.We have a reputation for being entrepreneur friendly.
Portfolio
317
Mentions
31
Employees: 11-50

Portfolio 317

DateNameWebsiteTotal RaisedLocation
11.09.2019Insilico M...insilico.com$682MUnited Sta...
25.04.2012iTutorGrou...tutor-group.com$115M-
-Chumanchumanapp.com-China, Gua...
-NEIWAIneiwai.heidianer.com$100M-
-KK Inc.kktv5.com--
-Kingswarekingsware.cn$72M-
-Insight Li...insight-med.com-China, Gua...
-Richenchina-richen.com.cn--
-Pratilipipratilipi.com$94.46MIndia
-???zuzuche.com-China, Gua...
Show more

Mentions in press and media 31

DateTitleDescription
29.04.2026Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 MillionBacked by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors SHANGHAI, April 29, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biote...
21.04.2026Alamar lists on Nasdaq, giving Qiming its fifth IPO in 2026Qiming Venture Partners has recorded its fifth IPO within its portfolio since the start of the year, after Alamar Biosciences officially began trading on Nasdaq on April 17. Founded in 2018, Alamar was established by a team led by scientist...
13.04.2026Vivatides Therapeutics Raises $54M in Series A FundingVivatides Therapeutics, a Suzhou, China- and Boston, MA-based biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, raised $54M in Series A funding. The round was co-led by Qiming Venture Partners, with partic...
02.01.2026AI Drug Discovery Pioneer Insilico Medicine Makes Landmark Hong Kong IPOInsilico Medicine, an AI drug discovery leader, made its Hong Kong Stock Exchange debut. The company raised HKD 2.277 billion. This was 2025's largest biotech IPO in Hong Kong. The offering was heavily oversubscribed, attracting global capi...
31.12.2025Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock ExchangeSHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The list...
09.12.2025Convergen: $10 Million Seed Funding Closed To Advance TrimTAC Protein Degradation PlatformConvergen has secured a $10 million Seed financing round to accelerate the development of its TrimTAC targeted protein degradation platform, designed to eliminate pathogenic multimeric protein aggregates linked to neurodegenerative diseases...
24.07.2021China Roundup: Kai-Fu Lee’s first Europe bet, WeRide buys a truck startupHello and welcome back to TechCrunch’s China Roundup, a digest of recent events shaping the Chinese tech landscape and what they mean to people in the rest of the world. Despite the geopolitical headwinds for foreign tech firms to enter Chi...
22.03.2021IDG, Qiming co-lead $70m Series B funding in biotech firm ZhenGePremium Contract development and manufacturing organisation (CDMO) firm Shanghai ZhenGe Biotechnology Co., Ltd has secured as much as $70 million in its Series B round of financing jointly led by China’s global VC Qiming Venture Partners an...
22.03.2021IDG, Qiming co-lead $70m Series B funding in biotech firm ZhenGeContract development and manufacturing organisation (CDMO) firm Shanghai ZhenGe Biotechnology Co., Ltd has secured as much as $70 million in its Series B round of financing jointly led by China’s global VC Qiming Venture Partners and return...
09.04.2020Qiming raises $1B fund, continuing big burst of VC activityQiming Venture Partners has raised a $1.1 billion venture fund. Building on its track record of backing biotechs such as CanSino and Zai Lab, Qiming pulled in its largest fund to date against a backdrop of COVID-19-fueled disruption. China’...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In